Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free TECX Stock Alerts

Tectonic Therapeutic (TECX) Competitors

Tectonic Therapeutic logo
$29.36 -0.29 (-0.98%)
Closing price 04:00 PM Eastern
Extended Trading
$29.72 +0.37 (+1.24%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TECX vs. AUPH, ZYME, STOK, BHC, and OCUL

Should you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Stoke Therapeutics (STOK), Bausch Health Cos (BHC), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.

How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?

Tectonic Therapeutic (NASDAQ:TECX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Tectonic Therapeutic currently has a consensus price target of $80.57, indicating a potential upside of 174.43%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 7.54%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tectonic Therapeutic is more favorable than Aurinia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tectonic Therapeutic
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Aurinia Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.27, suggesting that its share price is 227% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 3 mentions for Tectonic Therapeutic. Aurinia Pharmaceuticals' average media sentiment score of 0.82 beat Tectonic Therapeutic's score of 0.34 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurinia Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aurinia Pharmaceuticals has a net margin of 101.46% compared to Tectonic Therapeutic's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 27.47% beat Tectonic Therapeutic's return on equity.

Company Net Margins Return on Equity Return on Assets
Tectonic TherapeuticN/A -26.88% -25.83%
Aurinia Pharmaceuticals 101.46%27.47%19.61%

Aurinia Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tectonic TherapeuticN/AN/A-$74.15M-$4.05N/A
Aurinia Pharmaceuticals$283.06M7.36$287.20M$2.087.71

Summary

Aurinia Pharmaceuticals beats Tectonic Therapeutic on 9 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Zymeworks?

Tectonic Therapeutic (NASDAQ:TECX) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Tectonic Therapeutic presently has a consensus target price of $80.57, suggesting a potential upside of 174.43%. Zymeworks has a consensus target price of $37.89, suggesting a potential upside of 42.01%. Given Tectonic Therapeutic's higher probable upside, research analysts plainly believe Tectonic Therapeutic is more favorable than Zymeworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tectonic Therapeutic
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Zymeworks
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92

Tectonic Therapeutic has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tectonic TherapeuticN/AN/A-$74.15M-$4.05N/A
Zymeworks$105.97M18.57-$81.13M-$1.08N/A

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Zymeworks' average media sentiment score of 0.45 beat Tectonic Therapeutic's score of 0.34 indicating that Zymeworks is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zymeworks
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tectonic Therapeutic has a beta of 3.27, indicating that its share price is 227% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Tectonic Therapeutic has a net margin of 0.00% compared to Zymeworks' net margin of -76.56%. Zymeworks' return on equity of -26.00% beat Tectonic Therapeutic's return on equity.

Company Net Margins Return on Equity Return on Assets
Tectonic TherapeuticN/A -26.88% -25.83%
Zymeworks -76.56%-26.00%-20.57%

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Zymeworks beats Tectonic Therapeutic on 9 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Stoke Therapeutics?

Tectonic Therapeutic (NASDAQ:TECX) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Stoke Therapeutics had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for Stoke Therapeutics and 3 mentions for Tectonic Therapeutic. Stoke Therapeutics' average media sentiment score of 0.83 beat Tectonic Therapeutic's score of 0.34 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

62.6% of Tectonic Therapeutic shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -3.73%. Stoke Therapeutics' return on equity of -2.05% beat Tectonic Therapeutic's return on equity.

Company Net Margins Return on Equity Return on Assets
Tectonic TherapeuticN/A -26.88% -25.83%
Stoke Therapeutics -3.73%-2.05%-1.75%

Tectonic Therapeutic has a beta of 3.27, suggesting that its share price is 227% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Tectonic Therapeutic currently has a consensus target price of $80.57, indicating a potential upside of 174.43%. Stoke Therapeutics has a consensus target price of $41.83, indicating a potential upside of 26.92%. Given Tectonic Therapeutic's higher possible upside, equities research analysts clearly believe Tectonic Therapeutic is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tectonic Therapeutic
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Stoke Therapeutics
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.92

Stoke Therapeutics has higher revenue and earnings than Tectonic Therapeutic. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tectonic TherapeuticN/AN/A-$74.15M-$4.05N/A
Stoke Therapeutics$184.42M11.13-$6.89M-$0.12N/A

Summary

Stoke Therapeutics beats Tectonic Therapeutic on 9 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Bausch Health Cos had 14 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 17 mentions for Bausch Health Cos and 3 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.34 beat Bausch Health Cos' score of 0.27 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch Health Cos
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bausch Health Cos currently has a consensus price target of $8.00, indicating a potential upside of 41.72%. Tectonic Therapeutic has a consensus price target of $80.57, indicating a potential upside of 174.43%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Cos
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Tectonic Therapeutic
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bausch Health Cos has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Cos$10.53B0.20$157M-$3.24N/A
Tectonic TherapeuticN/AN/A-$74.15M-$4.05N/A

Bausch Health Cos has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.27, indicating that its stock price is 227% more volatile than the S&P 500.

Tectonic Therapeutic has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Bausch Health Cos' return on equity of 503.18% beat Tectonic Therapeutic's return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Cos-11.47% 503.18% 5.50%
Tectonic Therapeutic N/A -26.88%-25.83%

Summary

Bausch Health Cos and Tectonic Therapeutic tied by winning 8 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Tectonic Therapeutic has lower revenue, but higher earnings than Ocular Therapeutix. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$51.95M40.69-$265.94M-$1.44N/A
Tectonic TherapeuticN/AN/A-$74.15M-$4.05N/A

In the previous week, Ocular Therapeutix had 11 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 14 mentions for Ocular Therapeutix and 3 mentions for Tectonic Therapeutic. Ocular Therapeutix's average media sentiment score of 0.47 beat Tectonic Therapeutic's score of 0.34 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ocular Therapeutix presently has a consensus target price of $23.78, suggesting a potential upside of 144.88%. Tectonic Therapeutic has a consensus target price of $80.57, suggesting a potential upside of 174.43%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Ocular Therapeutix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79
Tectonic Therapeutic
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tectonic Therapeutic has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -511.90%. Tectonic Therapeutic's return on equity of -26.88% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-511.90% -70.68% -50.53%
Tectonic Therapeutic N/A -26.88%-25.83%

Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.27, suggesting that its stock price is 227% more volatile than the S&P 500.

Summary

Tectonic Therapeutic beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TECX vs. The Competition

Export
MetricTectonic TherapeuticMED IndustryMedical SectorNASDAQ Exchange
Market Cap$553.44M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-7.2538.8529.0428.47
Price / SalesN/A155.53476.6160.94
Price / CashN/A57.8827.6236.52
Price / Book2.197.039.676.67
Net Income-$74.15M$23.62M$3.55B$332.53M
7 Day Performance7.94%3.67%1.70%2.01%
1 Month Performance-3.80%7.16%5.62%9.20%
1 Year Performance37.26%67.03%34.42%39.59%

Tectonic Therapeutic Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TECX
Tectonic Therapeutic
3.0155 of 5 stars		$29.36
-1.0%		$80.57
+174.4%		N/A$553.44MN/AN/A120
AUPH
Aurinia Pharmaceuticals
2.8855 of 5 stars		$16.04
-2.0%		$17.25
+7.5%		N/A$2.13B$283.06M7.71300
ZYME
Zymeworks
2.4795 of 5 stars		$27.94
-2.2%		$37.89
+35.6%		N/A$2.11B$105.96MN/A460
STOK
Stoke Therapeutics
2.8439 of 5 stars		$33.33
-1.1%		$41.83
+25.5%		N/A$2.10B$184.42MN/A100
BHC
Bausch Health Cos
2.0562 of 5 stars		$5.69
+1.9%		$8.00
+40.7%		N/A$2.09B$10.27B13.5420,300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel